Skip to Content

VIDEO: Open Orphan’s Cathal Friel on pharma services firm’s plans and COVID-19 work (piworld) (ORPH)

Open Orphan (LSE:ORPH) is a rapidly-growing pharmaceutical services company with a focus on rare and orphan drugs.

Following its reverse takeover of hVIVO earlier this year, it has also become a world-leader in the provision of virology and vaccine challenge study services and viral laboratory services.

In the video below, provided by piworld, executive chairman Cathal Friel talks through what the firm does, the long-term opportunity it presents for investors, and its ongoing support work for companies developing coronavirus vaccinations.

piworld provides content for investors, by investors.

The organisation aims to help private investors get closer to companies and their management and – in turn – make more informed investment decisions.

Videos include:

•             Company results presentations

•             Management interviews

•             Company visits

•             Enlightened educational investor videos with investors, opinion formers, and industry leaders and Dynamic Investor Relations Ltd are not responsible for the content or accuracy of this article.  News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

  • Daniel Flynn does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the piece.
  • Dynamic Investor Relations Ltd, the owner of, has not been paid for the production of this piece by the company or companies mentioned above.

Related Articles


teathers app screenshot

App Empowering Private Investors

Crowd Equity for Placings, IPOs and Live Market Blockbuilds, designed to give provate investors access to placements and Intial Public Offerings (IPOs), predominantly on the London Stock Exchange’s Alternative Investment Market (AIM).